Skip to content
Menu

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.

Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.

Read at benzinga.com